CoChat

β-Cell–Specific Protein Kinase A Activation Enhances the Efficiency of Glucose Control by Increasing Acute-Phase Insulin Secretion

Open access

The DOI matches its Crossref record; 50 of the 51 references it cites were found in a registry or an index.

Abstract

Acute insulin secretion determines the efficiency of glucose clearance. Moreover, impaired acute insulin release is characteristic of reduced glucose control in the prediabetic state. Incretin hormones, which increase β-cell cAMP, restore acute-phase insulin secretion and improve glucose control. To determine the physiological role of the cAMP-dependent protein kinase (PKA), a mouse model was developed to increase PKA activity specifically in the pancreatic β-cells. In response to sustained hyperglycemia, PKA activity potentiated both acute and sustained insulin release. In contrast, a glucose bolus enhanced acute-phase insulin secretion alone. Acute-phase insulin secretion was increased 3.5-fold, reducing circulating glucose to 58% of levels in controls. Exendin-4 increased acute-phase insulin release to a similar degree as PKA activation. However, incretins did not augment the effects of PKA on acute-phase insulin secretion, consistent with incretins acting primarily via PKA to potentiate acute-phase insulin secretion. Intracellular calcium signaling was unaffected by PKA activation, suggesting that the effects of PKA on acute-phase insulin secretion are mediated by the phosphorylation of proteins involved in β-cell exocytosis. Thus, β-cell PKA activity transduces the cAMP signal to dramatically increase acute-phase insulin secretion, thereby enhancing the efficiency of insulin to control circulating glucose.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/db12-1013

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Figures

FIG. 1. Increased PKA activity in the islets of β-caPKA mice. A, PKA activity was measured in lysates prepared from islets of β-caPKA mice and control littermates using an in vitro assay. PKA activity was measured in the presence of 5 μmol/L exogenous cAMP (maximal PKA activity) and in the absence of added cAMP. B, Lysates prepared from islets of mice of all four genotypes were analyzed by immunoblotting and probed for PKA catalytic (PKA-Cα) and regulatory (PKA-RIα, RIIα, and RIIβ) subunits, and, for the loading control, PI-3 kinase p85 subunit (p85). One-way ANOVA, ***P < 0.01.
FIG. 1. Increased PKA activity in the islets of β-caPKA mice. A, PKA activity was measured in lysates prepared from islets of β-caPKA mice and control littermates using an in vitro assay. PKA activity was measured in the presence of 5 μmol/L exogenous cAMP (maximal PKA activity) and in the absence of added cAMP. B, Lysates prepared from islets of mice of all four genotypes were analyzed by immunoblotting and probed for PKA catalytic (PKA-Cα) and regulatory (PKA-RIα, RIIα, and RIIβ) subunits, and, for the loading control, PI-3 kinase p85 subunit (p85). One-way ANOVA, ***P < 0.01.CC BY-NC-ND · PubMed Central
FIG. 2. Insulin secretion in response to sustained hyperglycemia. The effects of sustained elevated glucose levels were analyzed using hyperglycemic clamps and by perifusion of isolated islets of Langerhans. A, In the hyperglycemic clamp, glucose levels were matched between β-caPKA (●) and wild-type littermate control (○) tamoxifen-treated mice at 200 mg/dL. Plasma insulin levels were subsequently measured in blood samples. Blood glucose and glucose infusion rates (B, C) are shown. D, Perifusion of islets isolated from β-caPKA (●) and wild-type littermate controls (○) was performed in Krebs-Ringer bicarbonate HEPES buffered saline (KRHB) using a change from 2 mmol/L glucose to 16.7 mmol/L glucose to stimulate both acute and sustained insulin secretion. Two-way ANOVA with Bonferroni posttest analyses. *P < 0.05; **P < 0.01; ***P < 0.001.
FIG. 2. Insulin secretion in response to sustained hyperglycemia. The effects of sustained elevated glucose levels were analyzed using hyperglycemic clamps and by perifusion of isolated islets of Langerhans. A, In the hyperglycemic clamp, glucose levels were matched between β-caPKA (●) and wild-type littermate control (○) tamoxifen-treated mice at 200 mg/dL. Plasma insulin levels were subsequently measured in blood samples. Blood glucose and glucose infusion rates (B, C) are shown. D, Perifusion of islets isolated from β-caPKA (●) and wild-type littermate controls (○) was performed in Krebs-Ringer bicarbonate HEPES buffered saline (KRHB) using a change from 2 mmol/L glucose to 16.7 mmol/L glucose to stimulate both acute and sustained insulin secretion. Two-way ANOVA with Bonferroni posttest analyses. *P < 0.05; **P < 0.01; ***P < 0.001.CC BY-NC-ND · PubMed Central
FIG. 3. Intraperitoneal glucose tolerance tests. Circulating insulin (A, C, E) and glucose (B, D, F) were measured after intraperitoneal glucose (1 g/kg, A and B; 0.5 g/kg, C and D; 3 g/kg, E and F) administration at 0 min. Plasma insulin was measured at 0, 2, 5, 10, 15, and 20 min and blood glucose was measured over the course of 120 min after glucose administration. β-caPKA, ●; wild-type, ○; PKA-CαR, □; MIP-CreERT, △. Area under the curve (AUC) for insulin and glucose were measured relative to baseline (y-axis = 0), and compared by Bonferroni posttest analyses (G, H). Two-way ANOVA showed significant difference between genotypes (P < 0.001) for (A–E). Bonferroni posttest analyses: *P < 0.05; ***P < 0.001.
FIG. 3. Intraperitoneal glucose tolerance tests. Circulating insulin (A, C, E) and glucose (B, D, F) were measured after intraperitoneal glucose (1 g/kg, A and B; 0.5 g/kg, C and D; 3 g/kg, E and F) administration at 0 min. Plasma insulin was measured at 0, 2, 5, 10, 15, and 20 min and blood glucose was measured over the course of 120 min after glucose administration. β-caPKA, ●; wild-type, ○; PKA-CαR, □; MIP-CreERT, △. Area under the curve (AUC) for insulin and glucose were measured relative to baseline (y-axis = 0), and compared by Bonferroni posttest analyses (G, H). Two-way ANOVA showed significant difference between genotypes (P < 0.001) for (A–E). Bonferroni posttest analyses: *P < 0.05; ***P < 0.001.CC BY-NC-ND · PubMed Central
FIG. 4. Measurement of parameters of β-cell mass. Islet area relative to pancreas area (A), islet number relative to pancreas area (B), and average islet size (C) were measured on pancreatic sections prepared from paraformaldehyde-fixed/paraffin-embedded pancreata stained for insulin and glucagon. Total pancreatic insulin content (D) was measured in acid extracted pancreata by ELISA. Comparison between wild-type (WT) and β-caPKA littermates showed no significant differences (P > 0.05, t test).
FIG. 4. Measurement of parameters of β-cell mass. Islet area relative to pancreas area (A), islet number relative to pancreas area (B), and average islet size (C) were measured on pancreatic sections prepared from paraformaldehyde-fixed/paraffin-embedded pancreata stained for insulin and glucagon. Total pancreatic insulin content (D) was measured in acid extracted pancreata by ELISA. Comparison between wild-type (WT) and β-caPKA littermates showed no significant differences (P > 0.05, t test).CC BY-NC-ND · PubMed Central
FIG. 5. Effects of β-cell PKA on the readily releasable granule pool and calcium signaling. A, Arginine tolerance tests were performed on overnight-fasted β-caPKA (●) and wild-type littermate control (○) mice by delivering 1 g/kg body weight i.p. l-arginine bolus in saline. B and C, Changes in cytoplasmic calcium was measured in response to a change from 2 mmol/L to 15 mmol/L glucose (B) and 30 mmol/L KCl in FURA-2–loaded islets isolated from β-caPKA (solid line) and control littermates (dotted line) mice. D, Membrane potential was measured by perforated patch electrophysiology in response to change in glucose from 2 mmol/L to 14 mmol/L glucose in islets isolated from β-caPKA (left) and control littermate (right) mice. Two-way ANOVA: A, P < 0.001; B and C, Not significant. Bonferroni posttest analysis: ***P < 0.001.
FIG. 5. Effects of β-cell PKA on the readily releasable granule pool and calcium signaling. A, Arginine tolerance tests were performed on overnight-fasted β-caPKA (●) and wild-type littermate control (○) mice by delivering 1 g/kg body weight i.p. l-arginine bolus in saline. B and C, Changes in cytoplasmic calcium was measured in response to a change from 2 mmol/L to 15 mmol/L glucose (B) and 30 mmol/L KCl in FURA-2–loaded islets isolated from β-caPKA (solid line) and control littermates (dotted line) mice. D, Membrane potential was measured by perforated patch electrophysiology in response to change in glucose from 2 mmol/L to 14 mmol/L glucose in islets isolated from β-caPKA (left) and control littermate (right) mice. Two-way ANOVA: A, P < 0.001; B and C, Not significant. Bonferroni posttest analysis: ***P < 0.001.CC BY-NC-ND · PubMed Central
FIG. 6. Oral glucose tolerance tests (OGTTs). Overnight-fasted control littermates (A, B) and β-caPKA (C, D) mice were administered 1 g/kg body weight glucose by oral gavage at 0 min. Blood for blood glucose (B, D) and plasma insulin (A, C) was sampled from the tail vein. Intraperitoneal (i.p.) glucose tolerance test (IPGTT) data from Fig. 2 is provided as dotted lines for comparison. Plasma insulin was measured over the 0- to 20-min interval and blood glucose was measured over the 0- to 120-min interval. Area under the curve (AUC) was calculated for each curve, relative to a y-axis value of 0. IPGTT, diamonds; OGTT, squares; open symbols and bars, controls; closed symbols and bars, β-caPKA. Two-way ANOVA comparison of IPGTT and OGTT: P < 0.05 for (A); P > 0.05 for (B–D). WT, wild-type. Bonferroni posttest analysis: *P < 0.05.
FIG. 6. Oral glucose tolerance tests (OGTTs). Overnight-fasted control littermates (A, B) and β-caPKA (C, D) mice were administered 1 g/kg body weight glucose by oral gavage at 0 min. Blood for blood glucose (B, D) and plasma insulin (A, C) was sampled from the tail vein. Intraperitoneal (i.p.) glucose tolerance test (IPGTT) data from Fig. 2 is provided as dotted lines for comparison. Plasma insulin was measured over the 0- to 20-min interval and blood glucose was measured over the 0- to 120-min interval. Area under the curve (AUC) was calculated for each curve, relative to a y-axis value of 0. IPGTT, diamonds; OGTT, squares; open symbols and bars, controls; closed symbols and bars, β-caPKA. Two-way ANOVA comparison of IPGTT and OGTT: P < 0.05 for (A); P > 0.05 for (B–D). WT, wild-type. Bonferroni posttest analysis: *P < 0.05.CC BY-NC-ND · PubMed Central
FIG. 7. Intraperitoneal glucose tolerance tests (IGTTs) after exendin-4 administration. Overnight-fasted β-caPKA and wild-type (WT) littermate control mice were administered exendin-4 15 min before receiving an 2 g/kg i.p. glucose bolus. Plasma insulin was measured over the subsequent 20 min (0–20 min) and blood glucose was measured over the −15- to 120-min interval. Area under the curve (AUC) was calculated for each curve relative to a y-axis value of 0. Diamonds, saline treated; squares, exendin-4 treated; open symbols and bars, controls; closed symbols and bars, β-caPKA. Two-way ANOVA indicated significant difference between IGTT and oral glucose tolerance test (P < 0.05) in (A–D). Bonferroni posttest analysis: *P < 0.05; **P < 0.01; ***P < 0.001.
FIG. 7. Intraperitoneal glucose tolerance tests (IGTTs) after exendin-4 administration. Overnight-fasted β-caPKA and wild-type (WT) littermate control mice were administered exendin-4 15 min before receiving an 2 g/kg i.p. glucose bolus. Plasma insulin was measured over the subsequent 20 min (0–20 min) and blood glucose was measured over the −15- to 120-min interval. Area under the curve (AUC) was calculated for each curve relative to a y-axis value of 0. Diamonds, saline treated; squares, exendin-4 treated; open symbols and bars, controls; closed symbols and bars, β-caPKA. Two-way ANOVA indicated significant difference between IGTT and oral glucose tolerance test (P < 0.05) in (A–D). Bonferroni posttest analysis: *P < 0.05; **P < 0.01; ***P < 0.001.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 50 references

Cited by

Metadata

Authors
Kaihara, K. A., Dickson, L. M., Jacobson, D. A., Tamarina, N., Roe, M. W., Philipson, L. H., & Wicksteed, B.
Affiliations
  • University of Chicago (US)
  • Vanderbilt University (US)
  • SUNY Upstate Medical University (US)
Corresponding author
Wicksteed, Barton
Venue
Diabetes
Published
2013-04-16
Volume
62
Issue
5
Pages
1527-1536
ISSN
  • 0012-1797 (ISSN-L)
  • 1939-327X
OpenAlex
W2143340315
Cited by
80
References
51
Citations by year
2026: 4 · 2025: 10 · 2024: 6 · 2023: 6 · 2022: 4 · 2021: 8 · 2020: 3 · 2019: 2 · 2018: 2 · 2017: 4 · 2016: 7 · 2015: 9 · 2014: 12 · 2013: 3
FWCI
10.19
Type
journal article
Language
en
Open access
Locations
  • Diabetes (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
  • American Diabetes Association (1-08-JF-58)
  • McKnight Foundation
  • University of Washington
  • National Institutes of Health (5t32dk087703-05, DK020595, DK063493)
  • Diabetes Research and Training Center (DK020595)
  • National Institute on Aging (F31AG035620)
  • National Institute of Diabetes and Digestive and Kidney Diseases (DK087703, DK-063493, R01DK048494, DK074966, R01DK085129, R01DK063493, T32-DK-087703, DK020595, DK-085129, DK-48494, R01DK092616, R01DK074966, P60DK020595, P30DK020595)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
Keywords
cAMP signaling, sustained insulin release, glycemic control, prediabetes, incretins, exendin-4, hyperglycemia, pancreatic beta cells, glucose clearance
MeSH terms
Exenatide, Insulin Secretion, Cyclic AMP, Animals, Crosses, Genetic, Enzyme Induction, Hyperglycemia, Hypoglycemic Agents, Insulin, Kinetics, Peptides, Phosphorylation, Protein Processing, Post-Translational, Venoms, Second Messenger Systems, Glucose Clamp Technique, Up-Regulation, Cyclic AMP-Dependent Protein Kinases, Patch-Clamp Techniques, Protein Subunits, Insulin-Secreting Cells, Mutant Proteins, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.